Extension Of Receiving Antiviral Drugs Reduces The Risk Of Lung Rejection After Transplantation

Extension Of Receiving Antiviral Drugs Reduces The Risk Of Lung Rejection After Transplantation.
Extended antiviral healing after a lung shift may ease prevent dangerous complications and organ rejection, a new study from Duke University Medical Center shows. A proletarian cause of infection in lung transplant recipients is cytomegalovirus (CMV), which often causes emollient effects but can be life-threatening for transplant patients. Standard preventive therapy involves taking the sedative valganciclovir (Valcyte) for up to three months. But even with this treatment, most lung transplant patients come about CMV infections within a year.

The Duke study included 136 patients who completed three months of voiced valganciclovir and then received either an additional nine months of placebo (66 patients) or an additional nine months of vocalized valganciclovir (70 patients). Since it was a double-blind, placebo-controlled randomized study, researchers compared two groups of randomly selected patients at 11 novel centers (one troop of which received the additional medication and a control party that received the placebo, with neither the researchers nor the participants knowing who was in the control group). Researchers found that CMV infection occurred in 10 percent of the extended remedying group, compared to 64 percent of the placebo group.